Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE-Lenvatinib vs TACE-Lenvatinib-Ablation for Recurrent HCC
NCT06609850Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Randomised, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression free survival at 24 months. Started Oct 2024; status: recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06609850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06609850.